Related references
Note: Only part of the references are listed.Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years
Giulio Disanto et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol
Petra Dirks et al.
BMC NEUROLOGY (2020)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Helmut Butzkueven et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials
Marcello Moccia et al.
FRONTIERS IN NEUROLOGY (2020)
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
T. Leist et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Clare Walton et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries
Rebecca Persson et al.
JOURNAL OF NEUROLOGY (2019)
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
Giancarlo Comi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Potential mechanisms of action related to the efficacy and safety of cladribine
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
An update on the safety of treating relapsing-remitting multiple sclerosis
Clara G. Chisari et al.
EXPERT OPINION ON DRUG SAFETY (2019)
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
Stuart Cook et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
Olaf Stuve et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Nordic Cancer Registries - an overview of their procedures and data comparability
Eero Pukkala et al.
ACTA ONCOLOGICA (2018)
Cladribine tablets added to IFN-β in active relapsing MS The ONWARD study
Xavier Montalban et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours
Maarit K. Leinonen et al.
EUROPEAN JOURNAL OF CANCER (2017)
Nordic registry-based cohort studies: Possibilities and pitfalls when combining Nordic registry data
John Maret-Ouda et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2017)
The Norwegian Multiple Sclerosis Registry and Biobank
K. -M. Myhr et al.
ACTA NEUROLOGICA SCANDINAVICA (2015)
The Swedish MS registry - clinical support tool and scientific resource
J. Hillert et al.
ACTA NEUROLOGICA SCANDINAVICA (2015)
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
Thomas P. Leist et al.
LANCET NEUROLOGY (2014)
Multiple sclerosis registries in Europe - results of a systematic survey
Peter Flachenecker et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
